Vectors Research Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $379K | Hold |
1,505
| – | – | 0.1% | 117 |
|
|
2026
Q1 | $327K | Buy |
1,505
+94
| +7% | +$20.9K | 0.1% | 119 |
|
|
2025
Q4 | $322K | Hold |
1,411
| – | – | 0.1% | 108 |
|
|
2025
Q3 | $327K | Hold |
1,411
| – | – | 0.1% | 113 |
|
|
2025
Q2 | $262K | Hold |
1,411
| – | – | 0.09% | 101 |
|
|
2025
Q1 | $296K | Hold |
1,411
| – | – | 0.1% | 96 |
|
|
2024
Q4 | $251K | Hold |
1,411
| – | – | 0.09% | 107 |
|
|
2024
Q3 | $279K | Hold |
1,411
| – | – | 0.08% | 110 |
|
|
2024
Q2 | $242K | Hold |
1,411
| – | – | 0.07% | 118 |
|
|
2024
Q1 | $257K | Sell |
1,411
-255
| -15% | -$43.9K | 0.07% | 121 |
|
|
2023
Q4 | $258K | Hold |
1,666
| – | – | 0.07% | 126 |
|
|
2023
Q3 | $241K | Sell |
1,666
-363
| -18% | -$53.3K | 0.08% | 117 |
|
|
2023
Q2 | $273K | Sell |
2,029
-100
| -5% | -$14.7K | 0.08% | 125 |
|
|
2023
Q1 | $339K | Sell |
2,129
-85
| -4% | -$13K | 0.09% | 115 |
|
|
2022
Q4 | $358K | Hold |
2,214
| – | – | 0.09% | 112 |
|
|
2022
Q3 | $297K | Sell |
2,214
-140
| -6% | -$20.1K | 0.08% | 115 |
|
|
2022
Q2 | $361K | Hold |
2,354
| – | – | 0.09% | 120 |
|
|
2022
Q1 | $382K | Sell |
2,354
-75
| -3% | -$10.9K | 0.08% | 120 |
|
|
2021
Q4 | $329K | Buy |
2,429
+151
| +7% | +$17.8K | 0.07% | 138 |
|
|
2021
Q3 | $246K | Sell |
2,278
-100
| -4% | -$11.4K | 0.06% | 142 |
|
|
2021
Q2 | $268K | Hold |
2,378
| – | – | 0.07% | 133 |
|
|
2021
Q1 | $257K | Sell |
2,378
-134
| -5% | -$14.3K | 0.07% | 126 |
|
|
2020
Q4 | $269K | Sell |
2,512
-179
| -7% | -$17.2K | 0.08% | 113 |
|
|
2020
Q3 | $225K | Buy |
2,691
+125
| +5% | +$11.8K | 0.08% | 115 |
|
|
2020
Q2 | $252K | Hold |
2,566
| – | – | 0.1% | 106 |
|
|
2020
Q1 | $196K | Sell |
2,566
-433
| -14% | -$36.9K | 0.09% | 105 |
|
|
2019
Q4 | $266K | Buy |
2,999
+755
| +34% | +$62.7K | 0.11% | 99 |
|
|
2019
Q3 | $170K | Hold |
2,244
| – | – | 0.08% | 117 |
|
|
2019
Q2 | $163K | Sell |
2,244
-350
| -13% | -$27.5K | 0.09% | 113 |
|
|
2019
Q1 | $209K | Buy |
2,594
+300
| +13% | +$24.5K | 0.12% | 100 |
|
|
2018
Q4 | $211K | Buy |
2,294
+50
| +2% | +$4.4K | 0.1% | 109 |
|
|
2018
Q3 | $209K | Buy |
+2,244
| New | +$213K | 0.13% | 98 |
|
Other funds holding ABBV
Vectors Research Management's ABBV Position: Q2 2026 in Review
Vectors Research Management held its AbbVie (ABBV) position steady in Q2 2026 at 1,505 shares worth $379K. The position accounts for 0.1% of the portfolio, ranked #117.
Vectors Research Management first reported a position in ABBV in Q3 2018 and has held it in 32 quarters since. The position peaked at $382K in Q1 2022. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Vectors Research Management held 1,505 shares of AbbVie worth $379K as of Q2 2026.
- Vectors Research Management left its AbbVie share count unchanged in Q2 2026.
- AbbVie made up 0.1% of Vectors Research Management's portfolio in Q2 2026, its #117 holding.
- Vectors Research Management first reported a position in AbbVie in Q3 2018 and has held it in 32 quarters since.
- Vectors Research Management's AbbVie position peaked at $382K in Q1 2022.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Vectors Research Management's 13F filing for Q2 2026, filed 29 Jul 2026.